Opens in a new tab

Zentiva France v Sanofi Mature IP (CFI, 24 January 2025)

Date24 January 2025
CourtCFI
DivisionMunich (DE) Local Division
Type of actionCounterclaim for revocation
Registry referenceCC_49716/2024 · ORD_68846/2024
PartiesZentiva France, Zentiva, k.s., Zentiva Pharma GmbH v. Sanofi Mature IP

Summary pending review. Official UPC registry metadata imported on 24 September 2026.

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

English summary awaiting review. Read the French case note.

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

No case number recorded in this record.

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Counterclaim for revocation
Outcome (Dhenne Avocats summary)
La division locale de Munich fixe la conférence intermédiaire au 17 juillet 2025 et les audiences du 14 au 17 octobre 2025 dans les procédures Sanofi relatives au brevet EP 2 493 466.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

  • EP 2 493 466 mentioned in: summary of the decision, Dhenne Avocats analysis Follow this patent
Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 2 493 466
Novel antitumoral use of cabazitaxel
recorded proprietor: Sanofi SA
Patent at issue according to the summary or official headnote
Also mentioned in 12 other decision(s): Sanofi v Reddy Pharma (CFI, 12 December 2025) · Accord Healthcare v Sanofi (Paris Judicial Court, RG 21/06416, 2024) · Sanofi v Accord Healthcare (CFI, ORD_69482/2024, 15 September 2025) · Sanofi v Accord Healthcare (CFI, ORD_69480/2024, 15 September 2025) · Sanofi v Accord Healthcare (CFI, 17 July 2025) · Sanofi v Zentiva France (CFI, 27 June 2025) · Sanofi v Accord Healthcare (CFI, 8 May 2025) · Medac v Sanofi Mature IP (CFI, 19 March 2025)
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: summary of the decision, Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.